The spleen of the yellow‐bellied toad, Bombina variegata , consists of distinct white and red pulps. The well‐developed white pulp is formed by a large central lymphocytic region around the numerous blood vessels and by its smaller peripheral ramifications, both surrounded by the more or less developed connective tissue boundary layer. Large peripheral sinuses of the white pulp, filled mostly with lymphocytes, are usually present at the inner side of this boundary. At the outer side of the boundary layer, the lymphocytic marginal zone is often observed. This zone merges into the erythrocyte‐rich red pulp formed by cellular cords and small venous sinusoids. The structure of the spleen of Bombina variegata differs considerably from the spleens of other anuran species studied so far. The highly developed white pulp and its distinct separation from the red pulp may be connected with the important role of the spleen as the main secondary lymphoid organ of B. variegata. The splenic compartmentalization makes the yellow‐bellied toads a useful model for experimental immunobiological studies.
Summary: Background: Peroxisome proliferator-activated receptor-γ (PPARγ) ligands were shown to induce the vascular endothelial growth factor (VEGF) synthesis in several cell types. We tested the effect of ciglitazone, one of the most specific PPARγ agonists, on the angiogenic activity of VEGF. Methods: Experiments were performed on human umbilical vein endothelial cell (HUVEC), incubated for 12 to 48 h with human VEGF165 (30 ng/ml) in the presence or absence of ciglitazone (1 – 10 µM). Cell proliferation was tested by BrdU incorporation. Migration was measured in modified Boyden chambers. Morphogenesis and capillary outgrowth were assessed by tube formation assay and spheroid cell culture, respectively. Results: Treatment with ciglitazone inhibited by about 50 % VEGF-induced proliferation, migration, morphogenesis, and sprouting of capillaries. Conclusions: Thus we conclude that, despite augmentation of VEGF generation, ciglitazone may act as an antiangiogenic agent attenuating VEGF activity by directly influencing endothelial cells. Zusammenfassung: Grundlagen: Peroxisome proliferator-activated receptor-γ (PPARγ)-Liganden induzieren die Synthese von Vascular Endothelial Growth Factor (VEGF) in verschiedenen Zellen. Methodik: Es wurde die Wirkung von Ciglitazon, einer der potentesten PPARγ-Agonisten, auf die angiogenetische Wirkung von VEGF untersucht. HUVEC (human umblical endothelial cells) wurden für 12 bis 48 Stunden mit humanem VEGF165 (30 ng/ml) sowohl mit, als auch ohne Ciglitazon (1 – 10 µM) inkubiert. Ergebnisse: Ciglitazon hat die angiogenetischen Aktivitäten von Endothelzellen gehemmt. Die Behandlung mit Ciglitazon hat die VEGF-induzierte Proliferation und Migration von HUVEC unterdrückt. Weiteres konnte mit der Ciglitazon-Behandlung eine Reduktion der morphogenetischen Kapazität von Endothelzellen („tube formation assay”) sowie ein vermindertes Aussprossen der Kapillaren (Sphärenzellkultur) nachgewiesen werden. Schlußfolgerungen: Obwohl Ciglitazon die Synthese von VEGF erhöht, hat Ciglitazon eine anti-angiogenetische Wirkung, welche durch Hemmung der VEGF-Aktivität und direkten Einfluß auf Endothelzellen bedingt ist.
Stem cells exist and can do a lot. For several decades, bone marrow and umbilical cord blood transplants containing haematopoietic stem cells have been used in the treatment of blood diseases. Genetic modifications (gene therapy) of such cells help to cure complex immunodeficiencies and severe anaemias. The limbal stem cells taken from the eye and properly multiplied can regenerate the damaged cornea, and the epidermal stem cells help in the treatment of severe burns and some hereditary, severe skin diseases. Promising experimental research is under way on other uses of stem cells. However, these cells are appropriately selected, having real ability to differentiate into specialized cells whose malfunction is the cause of the disease. Therapeutic applications of stem cells are apparently limited to date. Meanwhile, the Internet is full of advertisements for supposedly miraculous treatments for almost any disease. Stem cells have become a modern synonym of the Holy Grail. A wonderful dish, transforming every drink into elixir of health, youth and long life. Stem cells from a single source, e.g., umbilical cord blood, or so-called cells, although without proven properties of stem cells, are offered in commercial private clinics as a panacea for autism, cerebral palsy, spina bifida, eye diseases, amyotrophic lateral sclerosis and dozens other disorders. Without justification for their action in these diseases, without convincing evidence of safety, but for a high fee. This article discusses stem cells and misunderstandings about including any cells among them. It draws attention to the real possibilities and confirmed uses of stem cells and presents the problems, doubts and dangers for patients associated with commercial offers of treatments using “stem” cells. The author cites the positions of scientific institutions and societies warning against premature commercialization of unjustified and potentially dangerous therapies